RGN6024

About Reglagene

Reglagene is a privately held, pre-revenue biotech founded in 2018 in San Diego, California, with a mission to transform the treatment of brain diseases by overcoming the formidable challenge of the blood-brain barrier. The company's core technology platform centers on designing low molecular weight, tubulin-targeting small molecules that passively cross the BBB and are not substrates for efflux pumps, enabling sustained therapeutic action in the brain. Its lead candidate, RGN6024, has demonstrated compelling preclinical efficacy in glioblastoma models and is advancing towards an IND filing. The company is led by a seasoned team with deep pharmaceutical industry and scientific expertise, positioning it to address a significant unmet need in neuro-oncology.

Therapeutic Areas

Other Brain Cancers (e.g., Glioblastoma) Drugs